Zobrazeno 1 - 3
of 3
pro vyhledávání: '"G. S. Frick"'
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:P45-P45
Purpose To characterize the PK of DCL and FEX in adults identified as DSMs. Methods This was a randomized, double blind, crossover study with a 21-day washout between treatments. DSM subjects received DCL 5 mg or FEX HCI 180 mg QD for 7 days during e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57e1a0653d278aa3c7a3a4f8908def34
https://doi.org/10.1016/j.clpt.2004.12.066
https://doi.org/10.1016/j.clpt.2004.12.066
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:P9
Purpose To characterize the PK of DCL and 3-OH-DCL in SMs compared with normal metabolizers (NMs). DCL is metabolized to 3-OH-DCL by an unidentified enzyme(s). The product insert for DCL states that ~7% of the general population are apparent SMs, wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef3f87483ebf67e47eb95812890fe935
https://doi.org/10.1016/j.clpt.2003.11.033
https://doi.org/10.1016/j.clpt.2003.11.033
Autor:
Fawad J. Shah, G. Hajanóczky, G. S. Frick, Inez Ruiz-Stewart, Scott A. Waldman, Shiva Kazerounian, Giovanni Pitari, Muniswamy Madesh, Stephanie Schulz
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:P48
Guanylyl cyclase C (GCC) through cyclic GMP (cGMP) inhibits colorectal cancer cell proliferation, serving as a tumor suppressor in intestine. Conversely, Ca2+ entry through calcium release-activated calcium (Icrac) channels promotes colorectal cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c513065ac8a9044c2af6001f28105d53
https://doi.org/10.1016/j.clpt.2003.11.180
https://doi.org/10.1016/j.clpt.2003.11.180